BioSpace3h
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
alzheimersnewstoday3h
Leqembi IV monthly maintenance dosing approved by FDA
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
BioArctic stock rises on strong Leqembi sales
Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates. The ...
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...